
- /
- Supported exchanges
- / SHE
- / 002773.SHE
Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773 SHE) stock market data APIs
Chengdu Kanghong Pharmaceuticals Group Co Ltd Financial Data Overview
Chengdu Kanghong Pharmaceutical Group Co., Ltd research, develops, produces, and sells chemical drugs, chinese medicines, and biological products in China. It also develops ophthalmic medical devices. The company offers central nervous, digestive, and endocrine system drugs. Chengdu Kanghong Pharmaceuticals Group Co., Ltd. was founded in 1996 and is based in Chengdu, China.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Chengdu Kanghong Pharmaceuticals Group Co Ltd data using free add-ons & libraries
Get Chengdu Kanghong Pharmaceuticals Group Co Ltd Fundamental Data
Chengdu Kanghong Pharmaceuticals Group Co Ltd Fundamental data includes:
- Net Revenue: 4 559 M
- EBITDA: 1 484 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Chengdu Kanghong Pharmaceuticals Group Co Ltd Earnings data
What’s included:
- Latest Release: 2025-04-25
- EPS/Forecast: NaN
Get Chengdu Kanghong Pharmaceuticals Group Co Ltd End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Chengdu Kanghong Pharmaceuticals Group Co Ltd News

More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept
CHENGDU, China, Feb. 3, 2021 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong", SHE: 002773), has received Special Protocol Assessments from the Food and Drug Administration for three ...


More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept
CHENGDU, China, Feb. 3, 2021 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong", SHE: 002773), has received Special Protocol Assessments from the Food and Drug Administration for three ...

Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial
CHENGDU, China, Dec. 23, 2020 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong") announced a key development milestone of its key product conbercept last month. Kanghong is seeking glo...

Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial
CHENGDU, China, Dec. 23, 2020 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong") announced a key development milestone of its key product conbercept last month. Kanghong is seeking glo...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.